aldesleukin + cetuximab + fluorouracil + gemcitabine + irinotecan

This is a multi-agent combination regimen consisting of five drugs with distinct mechanisms of action, used experimentally in oncology, particularly for advanced or refractory solid tumors such as metastatic colorectal cancer. The components are: - **Aldesleukin** (recombinant interleukin-2): a cytokine therapy that stimulates the proliferation and activation of lymphocytes, enhancing immune-mediated tumor cell killing[1][4][5]. - **Cetuximab**: a chimeric monoclonal antibody targeting the epidermal growth factor receptor (EGFR), inhibiting EGFR-mediated signaling and promoting antibody-dependent cellular cytotoxicity[6][9]. - **Fluorouracil (5-FU)**: an antimetabolite chemotherapy agent that inhibits thymidylate synthase, disrupting DNA synthesis in rapidly dividing cells. - **Gemcitabine**: a nucleoside analog chemotherapy agent that incorporates into DNA during replication, causing chain termination and apoptosis. - **Irinotecan**: a topoisomerase I inhibitor that prevents DNA repair by stabilizing the cleavable complex between topoisomerase I and DNA, leading to double-strand breaks and cell death[7][10]. This combination aims to leverage both direct cytotoxic effects on tumor cells (via chemotherapeutics) and enhanced immune response against cancer cells (via aldesleukin and cetuximab). It has been studied in clinical trials for advanced colorectal cancer among other indications[6].